Jaceosidin overcomes osimertinib resistance in lung cancer by inducing G2/M cycle arrest through targeting DDB1
These findings offer new insights into the role of DDB1 in overcoming osimertinib resistance and suggest that combining jaceosidin with osimertinib may serve as a promising therapeutic strategy to enhance the efficacy of EGFR-TKIs treatment in resistant Non-small Cell Lung Cancer (NSCLC).
Authors
- Jianjun Jiang (ORCID: https://orcid.org/0000-0001-9178-8988)
- Zhijie Chen
- Meijuan Dian (ORCID: https://orcid.org/0000-0003-3726-0909)
- Shuan Rao (ORCID: https://orcid.org/0000-0002-5268-7006)
- Zehao Zhou (ORCID: https://orcid.org/0000-0001-5485-5600)
- Haiyan Ge (ORCID: https://orcid.org/0000-0001-7808-2403)
- Kaican Cai (ORCID: https://orcid.org/0000-0003-4664-6694)
- Yingying Liu (ORCID: https://orcid.org/0009-0005-0459-9107)
- Yun Liang (ORCID: https://orcid.org/0000-0003-0799-0054)
- Ruihao Zhang
- Yujing He (ORCID: https://orcid.org/0000-0003-3574-2357)
- Xuguang Rao
- Zhuoying Yang (ORCID: https://orcid.org/0009-0004-3784-0043)
- Biying Men (ORCID: https://orcid.org/0009-0005-8689-1928)
Institutions
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Toxicology and Applied Pharmacology
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1016/j.taap.2025.117327
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04